Loading...
OTCMSBHMY
Market cap7.60bUSD
Dec 16, Last price  
8.34USD
Name

Sino Biopharmaceutical Ltd

Chart & Performance

D1W1MN
OTCM:SBHMY chart
P/E
478.33
P/S
42.57
EPS
0.13
Div Yield, %
0.41%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
4.63%
Revenues
26.20b
-8.97%
1,119,075,526787,023,641736,635,8861,090,687,3752,009,498,7232,855,868,5013,482,314,0544,679,808,3936,704,567,4617,736,862,5109,898,228,01612,184,063,75914,170,151,72014,819,302,00020,888,584,00024,234,030,00023,647,224,00026,861,356,00028,780,412,00026,199,409,000
Net income
2.33b
-53.39%
179,345,8351,720,255,079141,553,227210,173,021262,051,334349,504,916483,123,793374,557,900717,232,356810,134,5051,210,019,7621,489,440,6601,713,153,9232,170,951,0009,046,347,0004,694,374,0004,340,667,00014,608,412,0005,002,618,0002,331,939,000
CFO
6.07b
-3.18%
242,135,043274,525,023112,559,141236,525,096365,890,986604,597,492428,388,791885,935,9691,294,881,2361,231,462,0531,839,326,3151,918,149,7833,090,825,2473,732,518,0005,094,364,0005,324,634,0005,325,336,0005,366,294,0006,265,155,0006,065,734,000
Dividend
Sep 11, 20240.076916 USD/sh
Earnings
Mar 26, 2025

Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
URL
http://www.sinobiopharm.com/
IPO date
Dec 08, 2003
Employees
26,079
Domiciled in
HK
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
26,199,409
-8.97%
28,780,412
7.14%
26,861,356
13.59%
Cost of revenue
20,529,530
22,692,117
21,782,800
Unusual Expense (Income)
NOPBT
5,669,879
6,088,295
5,078,556
NOPBT Margin
21.64%
21.15%
18.91%
Operating Taxes
797,267
775,986
1,957,880
Tax Rate
14.06%
12.75%
38.55%
NOPAT
4,872,612
5,312,309
3,120,676
Net income
2,331,939
-53.39%
5,002,618
-65.76%
14,608,412
236.55%
Dividends
(632,669)
(1,267,622)
(938,489)
Dividend yield
0.98%
1.46%
0.89%
Proceeds from repurchase of equity
(396,393)
(867,613)
399,876
BB yield
0.62%
1.00%
-0.38%
Debt
Debt current
11,207,428
9,723,841
6,585,038
Long-term debt
1,742,698
4,642,816
5,916,897
Deferred revenue
749,070
674,450
Other long-term liabilities
1,455,275
131,076
380,780
Net debt
(26,349,019)
(19,517,731)
(22,267,087)
Cash flow
Cash from operating activities
6,065,734
6,265,155
5,366,294
CAPEX
(1,067,823)
(1,705,612)
(1,893,984)
Cash from investing activities
(756,975)
(4,070,819)
(2,515,977)
Cash from financing activities
(6,548,990)
(3,186,390)
(3,225,263)
FCF
7,653,486
4,740,221
(624,956)
Balance
Cash
14,118,175
16,921,663
15,794,051
Long term investments
25,180,970
16,962,725
18,974,971
Excess cash
37,989,175
32,445,367
33,425,954
Stockholders' equity
37,445,183
31,681,310
30,924,747
Invested Capital
14,760,289
20,793,459
19,633,369
ROIC
27.41%
26.28%
16.71%
ROCE
10.86%
11.42%
9.87%
EV
Common stock shares outstanding
18,529,065
19,017,202
19,282,955
Price
3.47
-24.07%
4.57
-16.30%
5.46
-27.59%
Market cap
64,295,855
-26.02%
86,908,613
-17.45%
105,284,935
-25.73%
EV
45,642,320
85,665,167
99,683,683
EBITDA
6,744,163
7,135,279
6,071,112
EV/EBITDA
6.77
12.01
16.42
Interest
495,237
439,058
308,617
Interest/NOPBT
8.73%
7.21%
6.08%